#239 Need milk? Domperidone for increasing breast milk supply
CLINICAL QUESTION
What is the efficacy and safety of domperidone to increase milk supply in breastfeeding mothers?
BOTTOM LINE
In mothers of pre-term infants, domperidone increases milk volume by ~90 ml more than placebo after 14 days, with an additional 1 in 5 women experiencing a 50% increase in milk supply. Doses above 30 mg/day are likely not needed and may increase the risk of arrhythmias. Optimal length of treatment unknown.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Efficacy:
- Newest systematic review of 5 placebo-controlled trials of 192 breastfeeding mothers of pre-term infants. All used 10mg PO TID for 5-14 days:1
- Mean increase in expressed breast milk volume: 88 ml/day over placebo.
- Maternal adverse effects: no difference.
- Infant adverse effects: either no difference or not reported.
- Newest systematic review of 5 placebo-controlled trials of 192 breastfeeding mothers of pre-term infants. All used 10mg PO TID for 5-14 days:1
-
- Largest RCT from above systematic review (90 mother-baby pairs):2
- Women with 50% increase in milk supply at 14 days: 78% domperidone versus 58%, Number Needed to Treat (NNT)=5.
- Mean daily milk volume: 267 ml domperidone versus 168 ml (not statistically different, but likely underpowered).
- No difference in breastfeeding rates at 6 weeks.
- Largest RCT from above systematic review (90 mother-baby pairs):2
- Cardiac harms:
- Canadian observational study of 45,518 women given domperidone in the 6 months postpartum:3
- Risk of hospitalizations for ventricular arrhythmia: 1.3/10,000 (domperidone) versus 0.55/10,000 (no domperidone): no statistical difference.
- If real, would equal a number needed to harm of 12,950.
- Systematic review of 6 case control studies, mainly in men over age 60:4
- Arrythmia risk highest in doses >30 mg/day (OR=3.32) versus ≤30 mg/day (OR=1.63).
- Risk of hospitalizations for ventricular arrhythmia: 1.3/10,000 (domperidone) versus 0.55/10,000 (no domperidone): no statistical difference.
- Canadian observational study of 45,518 women given domperidone in the 6 months postpartum:3
- Small RCTs (7-15 women) found no difference in efficacy between 30mg/day and 60mg/day.5,6
- Low amounts of domperidone enter breastmilk (example <7mcg/day based on 80mg daily dose),7 but infant adverse effects similar to placebo.2,7
- In 2015, Health Canada warned of domperidone use and abnormal heart rhythms/sudden cardiac death. While available evidence may not apply to breastfeeding population, domperidone is contraindicated if risk of arrhythmias (examples cardiac disease/conduction abnormalities, concurrent QTc prolonging drugs or potent CYP3A4 inhibitors).8
- There is insufficient evidence on the use of herbal galactagogues (example fenugreek).9
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
